Security key
22978P106
Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE)
CUSIP: 22978P106
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Total 13F shares
- 11,759,494
- Total 13F value
- $12,816,995
- Share change
- -2,153,010
- Put/Call ratio
- 5.4%
- SEC-reported price per share
- $1.09
- Number of holders
- 55
- Value change
- -$1,528,241
- Number of buys
- 27
- Number of sells
- 12
- Shares outstanding
- 43,411,663
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
55
Top holders
10
CUE full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2025
Previous quarter: Q3 2024
Cue Biopharma, Inc. SEC filings
Cue Biopharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 22978P106
Recent filing periods:
Ownership snapshot
Top reported holders of CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Mark E. Strome
Disclosed value leader
Bleichroeder LP
Comparable rows
15/15
Latest evidence
30 Sep 2024
13D/G
13F
Lead comparable stake: 5%
13D/G row: Mark E. Strome
Showing 1-6 of 15 holder rows.
Quick read
Mark E. Strome leads the comparable SEC ownership view at 5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Mark E. Strome's linked filing trail.
Comparable ownership
Top 5
Mark E. Strome
5%
Slate Path Capital LP
1.4%
Bleichroeder LP
12%
VANGUARD GROUP INC
4.7%
BlackRock, Inc.
1.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Mark E. Strome |
13D/G
|
5%
|
$1,862,968
2,166,242 shares
|
$0 | 14 Nov 2022 |
| Slate Path Capital LP |
13F
13D/G
Company
|
1.4%
from 13D/G
|
$1,819,139
2,402,455 shares
|
— | 30 Sep 2024 |
| Bleichroeder LP |
13F
Company
|
12%
|
$3,783,910
4,997,240 shares
|
— | 30 Sep 2024 |
| VANGUARD GROUP INC |
13F
Company
|
4.7%
|
$1,537,786
2,031,421 shares
|
— | 30 Sep 2024 |
| BlackRock, Inc. |
13F
Company
|
1.3%
|
$432,342
570,975 shares
|
— | 30 Sep 2024 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
1.2%
|
$385,370
508,827 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
55
Shares
11,759,494
Rows available
55
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
50
Q4 2024 holders
55
Holder diff
5
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend